Justine A Barletta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5825828/publications.pdf

Version: 2024-02-01

80 papers 5,452 citations

32 h-index 72 g-index

81 all docs

81 docs citations

times ranked

81

5725 citing authors

#	Article	IF	CITATIONS
1	Glycolytic inhibition with 3-bromopyruvate suppresses tumor growth and improves survival in a murine model of anaplastic thyroid cancer. Surgery, 2022, 171, 227-234.	1.9	10
2	International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma. Journal of Clinical Oncology, 2022, 40, 96-104.	1.6	57
3	Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocrine Pathology, 2022, 33, 27-63.	9.0	388
4	Grading of Medullary Thyroid Carcinoma: an Interobserver Reproducibility Study. Endocrine Pathology, 2022, 33, 371-377.	9.0	13
5	Papillary Thyroid Carcinoma with High-Grade Features Versus Poorly Differentiated Thyroid Carcinoma: An Analysis of Clinicopathologic and Molecular Features and Outcome. Thyroid, 2021, 31, 933-940.	4.5	45
6	Completion Thyroidectomy is Less Common Following Updated 2015 American Thyroid Association Guidelines. Annals of Surgical Oncology, 2021, 28, 484-491.	1.5	12
7	Data set for reporting carcinoma of the thyroid: recommendations from the International Collaboration on Cancer Reporting. Human Pathology, 2021, 110, 62-72.	2.0	20
8	Genomics and Epigenomics of Medullary Thyroid Carcinoma: From Sporadic Disease to Familial Manifestations. Endocrine Pathology, 2021, 32, 35-43.	9.0	33
9	Predictors of Bilateral Disease in Pediatric Differentiated Thyroid Cancer. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4242-e4250.	3.6	10
10	Role of Sonographic Characteristics of Thyroid Bed Lesions Identified Following Thyroidectomy in the Diagnosis or Exclusion of Recurrent Cancer. Radiology, 2021, 299, 374-380.	7.3	8
11	Oncogenic Mutations in PI3K/AKT/mTOR Pathway Effectors Associate with Worse Prognosis in <i>BRAFV600E</i> -Driven Papillary Thyroid Cancer Patients. Clinical Cancer Research, 2021, 27, 4256-4264.	7.0	29
12	Evaluation of grade in a genotyped cohort of sporadic medullary thyroid carcinomas. Histopathology, 2021, 79, 427-436.	2.9	15
13	Genomic profile of columnar cell variant of papillary thyroid carcinoma. Histopathology, 2021, 79, 491-498.	2.9	10
14	Recipient of the 2021 Endocrine Pathology Society Lifetime Achievement Award: Dr. Ronald A. DeLellis. Endocrine Pathology, 2021, 32, 429-431.	9.0	2
15	Ketogenic diet combined with antioxidant N-acetylcysteine inhibits tumor growth in a mouse model of anaplastic thyroid cancer. Surgery, 2020, 167, 87-93.	1.9	20
16	A potential diagnostic pitfall for hobnail variant of papillary thyroid carcinoma. Histopathology, 2020, 76, 707-713.	2.9	14
17	Transcriptomic analysis of micropapillary high grade T1 urothelial bladder cancer. Scientific Reports, 2020, 10, 20135.	3.3	4
18	Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non–Muscle-Invasive Bladder Cancer. Cancer Research, 2020, 80, 4476-4486.	0.9	49

#	Article	IF	CITATIONS
19	Histopathologic Features and Clinical Outcome of Anaplastic Thyroid Carcinoma with a Minor Anaplastic Component. Endocrine Pathology, 2020, 31, 283-290.	9.0	11
20	Histological features of <i>BRAF</i> V600Eâ€mutant anaplastic thyroid carcinoma. Histopathology, 2020, 77, 314-320.	2.9	14
21	Anaplastic thyroid carcinoma. Seminars in Diagnostic Pathology, 2020, 37, 248-256.	1.5	23
22	A phase II study of nivolumab (N) plus ipilimumab (I) in radioidine refractory differentiated thyroid cancer (RAIR DTC) with exploratory cohorts in anaplastic (ATC) and medullary thyroid cancer (MTC) Journal of Clinical Oncology, 2020, 38, 6513-6513.	1.6	34
23	Unexpected Pathogenic RET p.V804M Variant Leads to the Clinical Diagnosis and Management of Medullary Thyroid Carcinoma. American Journal of Case Reports, 2020, 21, e927415.	0.8	O
24	Unexpected Pathogenic RET p.V804M Variant Leads to the Clinical Diagnosis and Management of Medullary Thyroid Carcinoma. American Journal of Case Reports, 2020, 21, e927415.	0.8	3
25	Prognostic Significance of Extent of Invasion in Poorly Differentiated Thyroid Carcinoma. Thyroid, 2019, 29, 1255-1261.	4.5	28
26	Characterization of Activating Mutations of the MEK1 Gene in Papillary Thyroid Carcinomas. Thyroid, 2019, 29, 1279-1285.	4.5	7
27	Differences in Thyroid Nodule Cytology and Malignancy Risk Between Children and Adults. Thyroid, 2019, 29, 1097-1104.	4.5	57
28	Everolimus in Anaplastic Thyroid Cancer: A Case Series. Frontiers in Oncology, 2019, 9, 106.	2.8	25
29	Clinicopathologic Features of Mismatch Repair-Deficient Anaplastic Thyroid Carcinomas. Thyroid, 2019, 29, 666-673.	4.5	24
30	Genetic Characteristics of Aldosterone-Producing Adenomas in Blacks. Hypertension, 2019, 73, 885-892.	2.7	121
31	Thyroid Tumors You Don't Want to Miss. Surgical Pathology Clinics, 2019, 12, 901-919.	1.7	7
32	Endocrine Pathology: Advances, Updates, and Diagnostic Pearls. Surgical Pathology Clinics, 2019, 12, xi-xii.	1.7	1
33	Tall Cell Variant of Papillary Thyroid Carcinoma: Impact of Change in WHO Definition and Molecular Analysis. Endocrine Pathology, 2019, 30, 43-48.	9.0	32
34	Impact of pure versus mixed metastatic urothelial carcinoma (mUC) histology on response with immune checkpoint inhibitors (ICIs) Journal of Clinical Oncology, 2019, 37, 479-479.	1.6	3
35	Molecular Testing of Nodules with a Suspicious or Malignant Cytologic Diagnosis in the Setting of Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP). Endocrine Pathology, 2018, 29, 68-74.	9.0	21
36	Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study. Clinical Cancer Research, 2018, 24, 1546-1553.	7.0	86

#	Article	IF	CITATIONS
37	<i>EPAS1</i> Mutations and Paragangliomas in Cyanotic Congenital Heart Disease. New England Journal of Medicine, 2018, 378, 1259-1261.	27.0	41
38	Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a review for pathologists. Modern Pathology, 2018, 31, 39-55.	5 . 5	107
39	Suggesting the cytologic diagnosis of noninvasive follicular thyroid neoplasm with papillaryâ€ike nuclear features (NIFTP): A retrospective analysis of atypical and suspicious nodules. Cancer Cytopathology, 2018, 126, 86-93.	2.4	27
40	A user's guide to nonâ€invasive follicular thyroid neoplasm with papillaryâ€like nuclear features (<scp>NIFTP</scp>). Histopathology, 2018, 72, 53-69.	2.9	40
41	Clinically Relevant Prognostic Parameters in Differentiated Thyroid Carcinoma. Endocrine Pathology, 2018, 29, 357-364.	9.0	18
42	Applications of Immunohistochemistry to Endocrine Pathology. Advances in Anatomic Pathology, 2018, 25, 413-429.	4.3	13
43	Should subcentimeter non-invasive encapsulated, follicular variant of papillary thyroid carcinoma be included in the noninvasive follicular thyroid neoplasm with papillary-like nuclear features category?. Endocrine, 2018, 59, 143-150.	2.3	57
44	Everolimus in anaplastic thyroid cancer: A case series Journal of Clinical Oncology, 2018, 36, e18112-e18112.	1.6	3
45	Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features Accounts for More Than Half of "Carcinomas―Harboring <i>RAS</i> Mutations. Thyroid, 2017, 27, 506-511.	4.5	84
46	The Flip Side of NIFTP: an Increase in Rates of Unfavorable Histologic Parameters in the Remainder of Papillary Thyroid Carcinomas. Endocrine Pathology, 2017, 28, 171-176.	9.0	24
47	Genetic and Histopathologic Intertumor Heterogeneity in Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1792-1796.	3.6	22
48	A case of primary secretory carcinoma of the thyroid with highâ€grade features. Histopathology, 2017, 71, 665-669.	2.9	15
49	Prevalence of Contralateral Tumors in Patients with Follicular Variant of Papillary Thyroid Cancer. Journal of the American College of Surgeons, 2017, 224, 1021-1027.	0.5	12
50	Radiationâ€associated neoplasia: clinical, pathological and genomic correlates. Histopathology, 2017, 70, 70-80.	2.9	65
51	Differential Growth Rates of Benign vs. Malignant Thyroid Nodules. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4642-4647.	3.6	38
52	Neoadjuvant chemotherapy prior to radical cystectomy for muscleâ€invasive bladder cancer with variant histology. Cancer, 2017, 123, 4346-4355.	4.1	138
53	Adrenocortical carcinoma and succinate dehydrogenase gene mutations: an observational case series. European Journal of Endocrinology, 2017, 177, 439-444.	3.7	23
54	Successful Management of a Patient with Malignant Thyroid Teratoma. Thyroid, 2017, 27, 125-128.	4.5	21

#	Article	IF	CITATIONS
55	Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer. Clinical Cancer Research, 2017, 23, 2367-2373.	7.0	24
56	Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma. JAMA Oncology, 2016, 2, 1023.	7.1	1,192
57	Preoperative Cytologic Diagnosis of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: A Prospective Analysis. Thyroid, 2016, 26, 1466-1471.	4.5	108
58	Features and Outcome of Autonomous Thyroid Nodules in Children: 31 Consecutive Patients Seen at a Single Center. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3856-3862.	3.6	29
59	Noninvasive Follicular Variant of Papillary Thyroid Carcinoma and the Afirma Gene-Expression Classifier. Thyroid, 2016, 26, 911-915.	4.5	62
60	<scp>HER2</scp> as a target in invasive urothelial carcinoma. Cancer Medicine, 2015, 4, 844-852.	2.8	41
61	<scp>GATA</scp> 3 expression in gestational trophoblastic tissues and tumours. Histopathology, 2015, 67, 636-644.	2.9	39
62	Absence of <scp>BRAF</scp> V600E in nonâ€infiltrative, nonâ€invasive follicular variant of papillary thyroid carcinoma. Histopathology, 2015, 67, 579-582.	2.9	44
63	Fine-Needle Aspiration Diagnoses of Noninvasive Follicular Variant of Papillary Thyroid Carcinoma. American Journal of Clinical Pathology, 2015, 144, 850-857.	0.7	108
64	BRAF V600E mutation-specific antibody: A review. Seminars in Diagnostic Pathology, 2015, 32, 400-408.	1.5	116
65	The Impact of Noninvasive Follicular Variant of Papillary Thyroid Carcinoma on Rates of Malignancy for Fine-Needle Aspiration Diagnostic Categories. Thyroid, 2015, 25, 987-992.	4.5	228
66	Targeted genomic profiling reveals recurrent KRAS mutations and gain of chromosome 1q in mesonephric carcinomas of the female genital tract. Modern Pathology, 2015, 28, 1504-1514.	5.5	111
67	Adrenal Tumors in Adults. Surgical Pathology Clinics, 2015, 8, 725-749.	1.7	13
68	Genomic landscape of high-grade T1 micropapillary bladder tumors Journal of Clinical Oncology, 2015, 33, 299-299.	1.6	0
69	Evaluating the frequency and functional consequences of epigenetic mutations on outcome derived from urothelial tumor sequencing in non-muscle invasive bladder cancer (NMIBC) Journal of Clinical Oncology, 2015, 33, e15519-e15519.	1.6	O
70	Somatic <i>ERCC2</i> Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma. Cancer Discovery, 2014, 4, 1140-1153.	9.4	506
71	How Are Childhood Thyroid Nodules Discovered: Opportunities for Improving Early Detection. Journal of Pediatrics, 2014, 164, 658-660.	1.8	23
72	Poorly Differentiated Thyroid Carcinoma. Surgical Pathology Clinics, 2014, 7, 475-489.	1.7	7

#	Article	IF	CITATIONS
73	Response and Acquired Resistance to Everolimus in Anaplastic Thyroid Cancer. New England Journal of Medicine, 2014, 371, 1426-1433.	27.0	290
74	Molecular Alterations in Partially-Encapsulated or Well-Circumscribed Follicular Variant of Papillary Thyroid Carcinoma. Thyroid, 2013, 23, 1256-1262.	4.5	104
75	Risk Stratification of Follicular Variant of Papillary Thyroid Carcinoma. Thyroid, 2013, 23, 273-279.	4.5	164
76	A phase II study of everolimus in patients with aggressive RAI refractory (RAIR) thyroid cancer (TC) Journal of Clinical Oncology, 2013, 31, 6023-6023.	1.6	19
77	Squamous cell carcinoma of the oral cavity (SCCOC) in young patients: The Dana Farber Cancer Institute experience Journal of Clinical Oncology, 2013, 31, 6054-6054.	1.6	O
78	Succinate Dehydrogenase-deficient Tumors. Advances in Anatomic Pathology, 2012, 19, 193-203.	4.3	66
79	Immunohistochemical Staining of Thyroidectomy Specimens for PTEN Can Aid in the Identification of Patients With Cowden Syndrome. American Journal of Surgical Pathology, 2011, 35, 1505-1511.	3.7	42
80	Prognostic significance of grading in lung adenocarcinoma. Cancer, 2010, 116, 659-669.	4.1	123